Altimmune (NASDAQ:ALT) Announces Earnings Results, Beats Expectations By $0.03 EPS

Altimmune (NASDAQ:ALT) issued its quarterly earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03, Zacks reports. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 52.60%. The company had revenue of $0.01 million for the quarter. During the same quarter last year, the company posted ($0.39) EPS.

Altimmune Stock Performance

ALT opened at $9.52 on Thursday. The stock has a market capitalization of $676.59 million, a PE ratio of -6.14 and a beta of 0.09. Altimmune has a one year low of $2.34 and a one year high of $14.84. The business’s 50 day moving average price is $6.95 and its 200 day moving average price is $6.89.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the transaction, the director now owns 41,958 shares of the company’s stock, valued at $289,510.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

ALT has been the topic of several recent research reports. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. UBS Group began coverage on shares of Altimmune in a report on Tuesday. They set a “buy” rating and a $26.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Thursday, August 22nd. Finally, B. Riley reiterated a “buy” rating and issued a $20.00 price objective on shares of Altimmune in a research report on Monday, August 12th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.00.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.